Nexalin Technology, Inc. (NXL) Fair Value 2026

NXL · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.6 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (42/100)

Quick Summary — As of 2026-10-07, Nexalin Technology, Inc. (NXL) trades at $4.50. QOC: 5.6/10. Value Trap Risk: 42/100 (WARN). 1/13 models active.

Key Facts

Ticker
NXL
Price
$4.50
Quality Score
5.6/10
Value Trap Risk
42/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Value Trap score of 42 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give NXL?

1 Intrinsic Value Models vs. Current Price ($4.50)

Core Models (Unlocked)
Model Fair Value Upside
Asset-Based · High Conviction
 $4.11 -8.7%

All Models Active

All 1 models are displayed above.

What Is Nexalin Technology, Inc. (NXL) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Nexalin Technology, Inc.'s intrinsic value is estimated at $4.11. Trading at its current price of $4.50, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -8.7%.

What Do the Models Say About NXL?

1 of 13 models are currently active for NXL. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does NXL Rank in Medical Devices?

Among 161 Medical Devices stocks, NXL ranks #113 by Quality of Company score. CirclFi's QOC score of 5.6/10 evaluates 32 fundamental signals. A score of 5.6 reflects mixed fundamentals.

See all Most Undervalued Medical Devices Stocks →

Nexalin Technology, Inc.'s positioning within the Medical Devices segment means that R&D productivity ratio plays an outsized role in fundamental analysis. The sector's unique characteristics — including licensing and M&A optionality — shape both the opportunity set and risk profile.

Is NXL a Value Trap?

CirclFi's Value Trap algorithm assigns NXL a score of 42/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Nexalin Technology, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Nexalin Technology, Inc. scores 5.6 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every NXL valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across NXL's 1 active models, average confidence is 51%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Nexalin Technology, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

NNOXNano-X Imaging Ltd.QOC 5.6PLSMPulsenmore Ltd.QOC 5.6NYXHNyxoah SAQOC 5.6LUCDLucid Diagnostics Inc.QOC 5.5BMRABiomerica, Inc.QOC 5.6GTHPGuided Therapeutics, Inc.QOC 5.5ODYYOdyssey Health, Inc.QOC 3.7BIOBio-Rad Laboratories, Inc.QOC 7.8RXSTRxSight, Inc.QOC 6.5IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: NNOX · PLSM · NYXH · LUCD · BMRA · GTHP · ODYY · BIO · RXST · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to NXL?

6 companies across all industries closest to NXL’s Quality of Company score of 5.6/10.

APAmpco-Pittsburgh CorporationQOC 5.6ASBPAspire Biopharma Holdings, Inc.QOC 5.6OPKOPKO Health, Inc.QOC 5.6GPROGoPro, Inc.QOC 5.6LZMHLZ Technology Holdings LimitedQOC 5.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: AP · ASBP · OPK · GPRO · LZMH · NVDA

Where Does NXL Sit in CirclFi's Medical Devices Rankings?

NXL is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Nexalin Technology, Inc.’s Valuation?

What is Nexalin Technology, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Nexalin Technology, Inc. (NXL). The Quality of Company score is 5.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is NXL overvalued or undervalued right now?

At $4.50, 0 of 1 active models suggest NXL may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Nexalin Technology, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 5.6 mean for NXL?

Nexalin Technology, Inc.'s QOC of 5.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on NXL?

CirclFi analyzes NXL with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is NXL a value trap in 2026?

Nexalin Technology, Inc.'s Value Trap score is 42/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Nexalin Technology, Inc. (NXL) a Quality of Company score of 5.6/10 across 32 fundamental signals as of 2026-10-07.” Source: circlfi.com/stock/NXL/ · Methodology
Primary sources for this NXL valuation
  • Financial statements: Nexalin Technology, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001527352) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for NXL as of ; valuations recomputed .